Merus Completes Acquisition of rights from UCB, Announces Q1 2016 Earnings Release Date

Pharmaceutical Investing

Merus Labs International Inc. (TSX:MSL, NASDAQ:MSLI) announced has completed the previously announced acquisition of rights to Elantan®, Isoket® and Deponit® in Europe and select other markets from UCB.

Merus Labs International Inc. (TSX:MSL, NASDAQ:MSLI) announced has completed the previously announced acquisition of rights to Elantan®, Isoket® and Deponit® in Europe and select other markets from UCB.
According to the press release:

Merus also announced today that it will release its fiscal earnings for the first quarter of fiscal 2016 after market close on Thursday, February 11, 2016. Merus will hold a conference call at 8:30am ET on Friday, February 12, 2016 to discuss the results. Conference call details will be provided in the results press release.

Click here to view the full press release.

The Conversation (0)
×